ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
Frequently asked questions
What sector does IMMUCELL CORP. DL-10 (IUL) operate in?
IMMUCELL CORP. DL-10 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is IMMUCELL CORP. DL-10 (IUL) current stock price?
As of the latest data, IMMUCELL CORP. DL-10 stock price is €9.05, with a previous close of €9.10. IMMUCELL CORP. DL-10 lost -€0.05 in the last trading session, representing a -0.55% loss.
What is IMMUCELL CORP. DL-10 (IUL) current market capitalization?
IMMUCELL CORP. DL-10 market cap is approximately 82.19 million.
What is IMMUCELL CORP. DL-10 (IUL) Earnings Per Share (EPS)?
The trailing EPS is €0.06.
What is IMMUCELL CORP. DL-10 (IUL) Price-to-Earnings (P/E) ratio?
IMMUCELL CORP. DL-10 current P/E ratio is 150.83.
What is IMMUCELL CORP. DL-10 (IUL) EBITDA?
IMMUCELL CORP. DL-10 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.14 million.
Does IMMUCELL CORP. DL-10 (IUL) pay dividends?
No. IMMUCELL CORP. DL-10 does not pay a dividend.
When is IMMUCELL CORP. DL-10 (IUL) next earnings report?
IMMUCELL CORP. DL-10 is expected to release its next earnings report on September 30, 2026.
What is IMMUCELL CORP. DL-10 (IUL) beta (volatility) score?
IMMUCELL CORP. DL-10 has a beta of 0.573, indicating lower volatility than the overall market.
